As pharmacologic options for presbyopia continue to expand, clinicians must move beyond simplistic “small pupil” treatment paradigms and toward a more individualized, lifestyle-driven approach to patient care. In this program, attendees will explore the differing mechanisms of action among emerging presbyopia therapies.

The course will examine how pupil size, depth of focus, contrast sensitivity, lighting conditions, and patient lifestyle demands all contribute to real-world functional vision outcomes. Through practical case discussions, participants will learn how to select therapies based not solely on near visual acuity, but on individualized patient goals, occupational needs, and environmental considerations. Attendees will also review how pharmacologic presbyopia therapies can be positioned as part of a comprehensive vision optimization strategy alongside glasses and contact lenses rather than as replacement therapies alone.

This program is supported in part by an independent medical educational grant from Mylan Inc., a Viatris Company.

Speaker: Cecelia Koetting, O.D., F.A.A.O., Dipl. ABO

Date: Thursday, October 8, 2026

Time: 5:30 PM - 6:30 PM Pacific Time

Location: Virtual

Moderator: Pending

Cost: Free!

COPE ID: Pending

Category: Pending

This event is undergoing COPE approval for 1 hour CE credit.